STOCK TITAN
  1. Home
  2. Sec-filings
  3. DMRA
  4. [Form 4] Galecto, Inc. Insider Trading Activity

Damora Therapeutics (DMRA) insiders receive 37,313-share option grant via Fairmount

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Damora Therapeutics, Inc. reported a Form 4 showing a grant of stock options linked to Fairmount-managed investment vehicles. An option for 37,313 shares of common stock with a $23.05 exercise price was awarded and is held indirectly by Peter Harwin for one or more Fairmount funds.

The option vests in equal monthly installments through March 23, 2029, contingent on Harwin’s continued service to Damora. Under his arrangement with Fairmount, any net cash or stock from this option must be turned over to Fairmount for the benefit of the relevant Fairmount fund, and the parties disclaim beneficial ownership beyond their pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest V L.P., Kiselak Tomas, Harwin Peter Evan
Role Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 10% Owner | Director, 10% Owner
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 37,313 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 37,313 shares (Indirect, By: Peter Harwin)
Footnotes (1)
  1. This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II LP ("Fund II") and Fairmount Healthcare Co-Invest V L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fairmount Funds Management LLC
(Last)(First)(Middle)
200 BARR HARBOR DRIVE
SUITE 400
(Street)
WEST CONSHOHOCKEN PENNSYLVANIA 19428
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Damora Therapeutics, Inc. [ DMRA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$23.0503/23/2026A37,313 (1)03/23/2036Common Stock37,313$037,313I(2)By: Peter Harwin
1. Name and Address of Reporting Person*
Fairmount Funds Management LLC
(Last)(First)(Middle)
200 BARR HARBOR DRIVE
SUITE 400
(Street)
WEST CONSHOHOCKEN PENNSYLVANIA 19428
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Fairmount Healthcare Fund II L.P.
(Last)(First)(Middle)
200 BARR HARBOR DRIVE
SUITE 400
(Street)
WEST CONSHOHOCKEN PENNSYLVANIA 19428
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Fairmount Healthcare Co-Invest V L.P.
(Last)(First)(Middle)
200 BARR HARBOR DRIVE
SUITE 400
(Street)
WEST CONSHOHOCKEN PENNSYLVANIA 19428
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Kiselak Tomas
(Last)(First)(Middle)
200 BARR HARBOR DRIVE
SUITE 400
(Street)
WEST CONSHOHOCKEN PENNSYLVANIA 19428
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Harwin Peter Evan
(Last)(First)(Middle)
200 BARR HARBOR DRIVE
SUITE 400
(Street)
WEST CONSHOHOCKEN PENNSYLVANIA 19428
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
2. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II LP ("Fund II") and Fairmount Healthcare Co-Invest V L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Remarks:
Fairmount, Fund II and Co-Invest may each be deemed a director by deputization of the Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount.
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC03/25/2026
/s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II L.P.03/25/2026
/s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Co-Invest V L.P.03/25/2026
/s/ Tomas Kiselak03/25/2026
/s/ Peter Harwin03/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Damora Therapeutics (DMRA) report on this Form 4?

Damora Therapeutics reported a grant of stock options. An option covering 37,313 shares of common stock was awarded with a $23.05 exercise price, held indirectly for Fairmount-managed investment vehicles rather than as a direct open-market purchase or sale by the individual.

Who is the primary beneficiary of the new Damora Therapeutics (DMRA) stock option grant?

The option is held for Fairmount funds, not personally. Although recorded under Peter Harwin, he holds the 37,313-share option for one or more Fairmount Healthcare funds and must deliver any net cash or stock to Fairmount for those investment vehicles’ benefit.

What are the key terms of the Damora Therapeutics (DMRA) option grant?

The grant covers 37,313 option shares at $23.05 each. The option represents a right to purchase Damora common stock and was issued at no cost on grant, with the stated exercise price applying if and when the option is exercised in the future.

How does the Damora Therapeutics (DMRA) option vest over time?

The option vests in equal monthly installments. Vesting continues through March 23, 2029, and each monthly vesting date requires Peter Harwin’s continued service to Damora Therapeutics, making the award contingent on ongoing involvement with the company over several years.

Does the Form 4 show an open-market buy or sell for Damora Therapeutics (DMRA)?

No open-market buy or sell is reported. The filing reflects a compensation-related option grant coded as an acquisition (A), with a zero grant price, rather than a purchase or sale of existing DMRA common shares on the open market.

How do Fairmount and its managers describe ownership of the Damora Therapeutics (DMRA) options?

They disclaim full beneficial ownership of the options. Fairmount, Peter Harwin, and Tomas Kiselak state that they disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest, emphasizing that the option is for Fairmount-managed investment vehicles.